Jeyaraman Madhan, Muthu Sathish, Jain Rashmi, Khanna Manish
Indian Stem Cell Study Group, Lucknow, Uttar Pradesh, India.
J Clin Orthop Trauma. 2020 Nov 26;13:134-142. doi: 10.1016/j.jcot.2020.11.015. eCollection 2021 Feb.
Systematic Review.
We performed this systematic overview on the overlapping meta-analyses that analyzed autologous bone marrow-derived mesenchymal stem cell(BM-MSC) therapy along with core decompression(CD) for the management of osteonecrosis of the femoral head(ONFH) and identify which study provides the current best evidence on the topic and generate recommendations for the same.
We conducted independent and duplicate electronic database searches in PubMed, Web of Science, Embase, Cochrane Database of Systematic Reviews, and the Database of Abstracts of Reviews of Effects till September 2020 for meta-analyses that analyzed the efficacy of BM-MSC therapy along with CD for ONFH. Methodological quality assessment was made using Oxford Levels of Evidence, AMSTAR scoring, and AMSTAR 2 grades. We then utilized the Jadad decision algorithm to identify the study with the highest quality to represent the current best evidence to generate the recommendation.
6 meta-analyses fulfilling the eligibility criteria were included. The AMSTAR scores of the included studies varied from 4 to 9 (mean:7) and all the included studies had critically low reliability in their summary of results due to their methodological flaws according to AMSTAR 2 grades. The current best evidence showed that utilization of BM-MSC therapy along with CD for ONFH resulted in significant improvement in Harris hip scores at 12 and 24 months along with a significant reduction in the necrotic area of the femoral head and the rate of conversion to total hip arthroplasty(THA) without a significant rise in adverse events due to the procedure.
Based on this systematic overview, we give a Level II recommendation that BM-MSC therapy is more efficacious along with CD in the management of ONFH compared to CD alone. BM-MSC therapy provides better pain relief with significant functional improvement and delaying the collapse of the femoral head thereby preventing further treatment such as THA.
系统评价。
我们对重叠的荟萃分析进行了这项系统综述,这些荟萃分析分析了自体骨髓间充质干细胞(BM-MSC)疗法联合髓芯减压(CD)治疗股骨头坏死(ONFH)的情况,并确定哪项研究提供了关于该主题的当前最佳证据,并为此提出建议。
我们在PubMed、科学网、Embase、Cochrane系统评价数据库和循证医学数据库中进行了独立且重复的电子数据库检索,直至2020年9月,以查找分析BM-MSC疗法联合CD治疗ONFH疗效的荟萃分析。使用牛津证据水平、AMSTAR评分和AMSTAR 2分级进行方法学质量评估。然后,我们利用Jadad决策算法确定质量最高的研究,以代表当前最佳证据来提出建议。
纳入了6项符合纳入标准的荟萃分析。纳入研究的AMSTAR评分从4到9不等(平均:7),根据AMSTAR 2分级,所有纳入研究由于其方法学缺陷,在结果总结方面的可靠性极低。当前最佳证据表明,BM-MSC疗法联合CD治疗ONFH可使12个月和24个月时的Harris髋关节评分显著改善,同时股骨头坏死面积和全髋关节置换术(THA)转化率显著降低,且该手术导致的不良事件无显著增加。
基于这项系统综述,我们给出二级推荐,即与单纯CD相比,BM-MSC疗法联合CD治疗ONFH更有效。BM-MSC疗法能更好地缓解疼痛,显著改善功能,延缓股骨头塌陷,从而避免进一步治疗,如THA。